Find information on thousands of medical conditions and prescription drugs.

Compazine

Prochlorperazine is a highly potent neuroleptic, which is 10 to 20-times more potent than chlorpromazine. It is a typical antipsychotic drug of the phenothiazine class sold under the names Compazine®, Buccastem® and Stemetil®. more...

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

It is now relatively seldom used for the treatment of psychosis and the manic phase of bipolar disorder. It has a prominent antiemetic/antivertignoic activity and is more often used for the (short-time) treatment of nauses/emesis and vertigo as follows:

1.To alleviate the symptoms of vertigo

2. As an antiemetic, particularly for nausea and vomiting caused by cancer treatment and in the pre- and postoperative setting

3. Quite recently, in the UK prochlorperazine maleate has been made available as Buccastem M® in buccal form as an OTC-treatment for migraine. In this indication it blocks the CTZ (Chemical Trigger Zone) in the brain, which is responsible for causing severe nausea and emesis. Its OTC use is strictly restricted to a maximum of 2 days, because of the potentially severe side-effects of Procloperazine, which mandate supervision by a health care provider.

Prochlorperazine is available as an oral liquid, tablets, and suppositories, as well as in an injectable form.

Following i.m.-injection the antiemetic action is evident within 5 to 10 minutes and lasts for 3 to 4 hours. Rapid action is also noted after buccal treatment. With oral dosing the start of action is delayed but the duration somewhat longer (approximately 6 hours).

Due to the short duration of treatment it is usually well tolerated. It shares in general all side-effects of chlorpromazine, but these are seen less frequently so and are less disturbing to the patient, particularly as most patients with the aforementioned conditions are hospitalized. In the treatment of nauses/emesis it might be given together with an antiparkinsonian drug to prevent extrapyramidal side effects of prochlorperazine.

If treating psychotic conditions on a long-term basis, the high incidence of early and late (tardive dyskinesia) extrapyramidal side-effects should be considered carefully. Prochlorperazine has in the long-term treatment approximately the same incidence and severity of extrapyramidal side-effects as haloperidol.

Read more at Wikipedia.org


[List your site here Free!]


Prochlorperazine more effective than ketorolac for pediatric migraine
From Journal of Family Practice, 6/1/04

Brousseau DC, Duggy SJ, Anderson AC, Linakis JG. Treatment of pediatric migraine headaches. A randomized, double-blind trial of prochlorperazine versus ketorolac. Ann Emerg Med 2004; 43:256-262.

* CLINICAL QUESTION

Is ketorolac more effective than prochlorperazine in the treatment of pediatric migraine in the emergency setting?

* BOTTOM LINE

Prochlorperazine (Compazine) is more effective than ketorolac (Toradol) in the treatment of children presenting to the emergency department with migraine. One additional child will experience headache relief for every 4 children receiving prochlorperazine instead of ketorolac. (LOE=1b)

* STUDY DESIGN

Randomized controlled trial (double-blinded)

* SETTING

Emergency department

* SYNOPSIS

This study is a start in the right direction toward clearing up the lack of information regarding treatment of pediatric migraine in the emergency department. The investigators recruited 62 children aged 5 to 18 years presenting with migraine in either of 2 pediatric emergency departments. Migraine was defined as recurrent headache with at least 3 of the following symptoms: an aura; unilateral location; throbbing pulsatile pain; nausea, vomiting, or abdominal pain; relief after sleep; and a family history of migraine.

Using concealed allocation, researchers randomized patients deemed to require intravenous medication to receive either prochlorperazine 0.15 mg/kg, up to 10 mg, or ketorolac 0.5 mg/kg, up to 30 mg, over 10 minutes. Children not experiencing at least a 50% reduction in pain within 60 minutes were given the alternative study drug and evaluated again.

Using the Nine Faces Pain Scale, 85% of prochlorperazine-treated children and 55% of ketorolac-treated patients experienced at least a 50% relief in pain (number needed to treat [NNT]=4; 95% confidence interval [CI], 2-13). One third of children treated with prochlorperazine achieved complete relief, compared with 7% of children receiving ketorolac (NNT=4; 95% CI, 2-13). Headache recurrence within the following 2 days occurred at a similar rate in both groups (27% and 31%, respectively).

COPYRIGHT 2004 Dowden Health Media, Inc.
COPYRIGHT 2004 Gale Group

Return to Compazine
Home Contact Resources Exchange Links ebay